


Journal Pre-proof

Development and field validation of an RT-LAMP assay for the rapid detection of chikungunya virus in patient and mosquito samples

Severino Jefferson Ribeiro da Silva, Jurandy Júnior Ferraz de Magalhães, Quinn Matthews, Ana Luisa Lot Divarzak, Renata Pessôa Germano Mendes, Bárbara Nazly Rodrigues Santos, Diego Guerra de Albuquerque Cabral, Jacilane Bezerra da Silva, Alain Kohl, Keith Pardee, Lindomar Pena



PII: S1198-743X(24)00116-2

DOI: <https://doi.org/10.1016/j.cmi.2024.03.004>

Reference: CMI 3577

To appear in: *Clinical Microbiology and Infection*

Received Date: 3 September 2023


Revised Date: 2 March 2024

Accepted Date: 4 March 2024

Please cite this article as: Ribeiro da Silva SJ, Ferraz de Magalhães JJ, Matthews Q, Lot Divarzak AL, Germano Mendes RP, Rodrigues Santos BN, Guerra de Albuquerque Cabral D, Bezerra da Silva J, Kohl A, Pardee K, Pena L, Development and field validation of an RT-LAMP assay for the rapid detection of chikungunya virus in patient and mosquito samples, *Clinical Microbiology and Infection*, <https://doi.org/10.1016/j.cmi.2024.03.004>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2024 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.



1 **Development and field validation of an RT-LAMP assay for the rapid**
2 **detection of chikungunya virus in patient and mosquito samples**

3 Severino Jefferson Ribeiro da Silva^{1,2*}, Jurandy Júnior Ferraz de
4 Magalhães^{1,3,4,5}, Quinn Matthews², Ana Luisa Lot Divarzak², Renata Pessoa
5 Germano Mendes¹, Bárbara Nazly Rodrigues Santos¹, Diego Guerra de
6 Albuquerque Cabral³, Jacilane Bezerra da Silva³, Alain Kohl^{6,7}, Keith Pardee^{2,8},
7 Lindomar Pena^{1*}

8 ¹Laboratory of Virology and Experimental Therapy (Lavite), Department of Virology, Aggeu
9 Magalhães Institute (IAM), Oswaldo Cruz Foundation (Fiocruz), 50670-420, Recife,
10 Pernambuco, Brazil.

11 ²Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON M5S 3M2, Canada.

12 ³Department of Virology, Pernambuco State Central Laboratory (LACEN/PE), Recife,
13 Pernambuco, Brazil.

14 ⁴University of Pernambuco (UPE), Serra Talhada Campus, 56909-335 Serra Talhada,
15 Pernambuco, Brazil.

16 ⁵Public Health Laboratory of the XI Regional Health, 56912-160 Serra Talhada, Pernambuco,
17 Brazil

18 ⁶MRC-University of Glasgow Centre for Virus Research, Glasgow G61 1QH, UK.

19 ⁷Department of Vector Biology and Tropical Disease Biology, Liverpool School of Tropical
20 Medicine, Liverpool L3 5QA, UK.

21 ⁸Department of Mechanical and Industrial Engineering, University of Toronto, Toronto, ON,
22 Canada.

23 *Co-corresponding authors:

24 Severino Jefferson Ribeiro da Silva, Ph.D. Emails: jeffersonbiotecviro@gmail.com ,
25 jefferson.silva@utoronto.ca

26 Lindomar Pena, Ph.D. Email: lindomar.pena@fiocruz.br

27

28

29

30 **ABSTRACT**

31 **Objectives**

32 We aimed to develop a reverse transcription loop-mediated isothermal
33 amplification (RT-LAMP) platform for the rapid detection of CHIKV in both
34 patient and mosquito samples from Brazil.

35 **Methods**

36 We optimized an RT-LAMP assay, then evaluated the sensitivity and specificity
37 using visual detection. In comparison with the RT-qPCR reference method, we
38 validated the utility of this assay as a molecular diagnostic test in a reference
39 laboratory for arbovirus diagnostics using 100 serum samples collected from
40 suspected CHIKV cases.

41 **Results**

42 Our RT-LAMP assay specifically detected CHIKV without cross-reactivity
43 against other arboviruses. The limit of detection of our RT-LAMP was estimated
44 in -1.18 PFU (confidence interval [CI] ranging from -2.08 to 0.45), resulting in a
45 similar analytical sensitivity when directly compared to the gold standard RT-
46 qPCR assay. Then, we demonstrate the ability of our RT-LAMP assay to detect
47 the virus in different human specimens (serum, urine, and saliva), and crude
48 lysate of *Aedes aegypti* mosquitoes in as little as 20-30 minutes and without a
49 separate RNA isolation step. Lastly, we showed that our RT-LAMP assay could
50 be lyophilized and reactivated by adding water, indicating potential for room-
51 temperature storage. Our RT-LAMP had a clinical sensitivity of 100% (95% CI,
52 90.97% to 100.00%), clinical specificity of 96.72% (95% CI, 88.65% to 99.60%),
53 and overall accuracy of 98.00% (95% CI, 92.96% to 99.76%).

54 **Conclusions**

55 Taken together, these findings indicate that the RT-LAMP assay reported here
56 solves important practical drawbacks to the deployment of molecular
57 diagnostics in the field and can be used to improve testing capacity, particularly
58 in low- and middle-income countries.

59 **Keywords:** RT-LAMP; CHIKV; diagnostic; point-of-care; patients; mosquitoes.

60 INTRODUCTION

61 Chikungunya virus (CHIKV) is an arbovirus member of the genus *Alphavirus*,
62 family *Togaviridae*¹. In most patients, CHIKV infection is typically accompanied
63 by a sudden onset of fever, myalgia, vomiting, rash, nausea, fatigue, headache,
64 and arthralgia, with severe cases causing neurological manifestations observed
65 in the elderly^{2, 3} and/or chronic polyarthralgia that can persist for months^{4, 5}. In
66 countries affected by other endemic arboviruses, such as Zika virus (ZIKV) and
67 dengue virus (DENV), the clinical diagnosis of CHIKV infection becomes
68 extremely difficult due to the similar clinical presentation.

69 Currently, RT-qPCR is considered the reference method for the detection of
70 CHIKV from patient and mosquito samples⁶. Although sensitive and specific,
71 RT-qPCR requires specialized laboratory instrument and involves the use of
72 multistep protocols, leading to limited availability outside of high-resource
73 settings and slow turnaround time of several days or weeks, thus delaying
74 clinical decision-making and therapeutic management of patients.

75 An alternative to RT-qPCR is reverse-transcription loop-mediated isothermal
76 amplification (RT-LAMP)⁷⁻¹¹, which has been widely used for the detection of
77 RNA viruses such as Zika virus⁷, dengue virus¹², Ebola virus¹³, and SARS-CoV-
78 2¹⁴⁻¹⁶. This isothermal amplification method enables rapid and sensitive
79 detection of a biomarker gene sequences¹⁰ and – unlike RT-qPCR – RT-LAMP
80 amplification of viral target occurs at a constant temperature and the results can
81 be easily read with the naked eye^{7, 8, 17}. Thanks to its notable simplicity and
82 high performance, much effort has been put towards the development of RT-
83 LAMP assays during the COVID-19 pandemic, and the potential of field
84 application has been recognized¹⁷⁻²⁰.

85 Here, we report a rapid, low-cost RT-LAMP assay for the detection of CHIKV in
86 different human samples, including serum, saliva, urine, and crude lysate of
87 *Aedes aegypti* mosquitoes. We then demonstrate the ability to lyophilize our
88 RT-LAMP platform, indicating potential for room-temperature storage.

89

90 **METHODS**

91 **Synthetic RNA control for molecular reactions**

92 DNA encoding the chikungunya virus target was obtained from the Sangon
93 Biotech Co. (China) in a pUC57 backbone. *In vitro* T7 RNAP-based
94 transcription of synthetic RNA was done overnight using the HiScribe T7 Quick
95 High Yield RNA Synthesis Kit (E2050S, NEB) following the manufacturer's
96 instructions.

97 **Cells and viruses**

98 Vero cells were maintained in Dulbecco's modified Eagle's medium (DMEM)
99 (Gibco, Carlsbad, CA) at 37°C under 5% CO₂. CHIKV strain PE2016-480 used
100 in this study belongs to the ECSA genotype (unpublished) and was isolated
101 from a patient serum in Pernambuco State, Brazil. Similarly, other arboviruses
102 (DENV [1-4], YFV, ZIKV, and MAYV) were propagated in Vero cells and titrated
103 by plaque assay.

104 **Optimization of the CHIKV RT-LAMP assay**

105 To optimize RT-LAMP for CHIKV detection, different reaction settings were
106 tested as we have previously described for ZIKV⁹. Briefly, 25 µL RT-LAMP
107 reactions were prepared in triplicates containing 1x buffer, 4 U Bst DNA
108 Polymerase [version 3.0, NEB], 8 mM MgSO₄, 1.4 mM deoxynucleotides
109 triphosphates (dNTPs) (ThermoFisher Scientific), 0.2 µM for F3, 0.2 µM for B3,
110 1.6 µM for FIP, 1.6 µM for BIP, 0.4 µM for LF, 0.4 µM for LB primers, and 5.0 µL
111 of template. The WarmStart LAMP 4X Master Mix (Lyo-compatible, M1710B,
112 NEB) were assembled in 25 µL following the manufacturer's instructions. The
113 CHIKV RT-LAMP primers targeted the envelope gene (6K-E1) of the genome in
114 both genotypes (Asian and ECSA) (Supplementary Data 1)²¹. All reactions were
115 set-up on ice, incubated at 65°C for 30 minutes, then inactivated at 80°C for 5
116 minutes. RT-LAMP amplicons were analyzed using four different approaches as
117 described previously⁹. For real time detection, amplicons were visualized by
118 adding 0.5 µL of 1x LAMP Fluorescent Dye (B1700S, NEB).

119

120 Lyophilization of RT-LAMP reactions and storage at room temperature

121 Unless otherwise mentioned, RT-LAMP reactions were mixed as described
122 above (excluding dye and sample) and aliquoted into 1.5 mL tubes. The tubes
123 were then punctured twice in the cap with a 22 G needle and frozen using liquid
124 nitrogen. Tubes were then rapidly transferred into a vacuum concentrator
125 connected to the lyophilizer equipment (FreeZone 6 Liter – 84°C Console
126 Freeze Dryer) and lyophilized as described previously ²².

127 Viral RNA extraction and RT-qPCR assay for CHIKV detection

128 Viral RNA was extracted from samples using QIAamp Viral RNA Mini Kit
129 (52906, Qiagen) according to the manufacturer's instructions. Samples were
130 assayed for positivity and analyzed by RT-qPCR according to protocols
131 established by the US CDC (positive samples: cycle quantification [Cq] ≤ 37) ⁶.
132 Primers and probe were synthesized by IDT and can be found in Supplementary
133 Data 1. The RNA copy numbers of CHIKV in each reaction was estimated by
134 comparing the Cq values to the standard curve made by 10-fold serial dilutions
135 of CHIKV transcript (Fig. S1).

**136 Analytical specificity and sensitivity of RT-LAMP assay for CHIKV
137 detection**

138 To determine the analytical specificity of the CHIKV RT-LAMP, the primers were
139 tested to detect only CHIKV against a panel of different arboviruses (Table S1).
140 To evaluate the analytical sensitivity of the RT-LAMP assay, a 10-fold serial
141 dilution of CHIKV was made in human serum. Virus concentration in spiked
142 specimens ranged from 10^5 to 10^{-7} PFU. In parallel, viral RNA from the same
143 dilutions was extracted and then tested with the RT-qPCR method ⁶.

**144 Human biological and mosquito samples experiments under controlled
145 conditions**

146 To evaluate the ability of the RT-LAMP to detect CHIKV in human and mosquito
147 samples, we spiked serum, saliva, urine and crude lysate of *Ae. Aegypti*
148 mosquitoes with two clinically viral loads: 10^6 PFU/mL and 10^3 PFU/mL, as
149 described previously⁹.

150 Field validation using patient samples

151 A total of 100 clinical samples were obtained from patients in Pernambuco
152 State, Brazil, with suspected arbovirus infection during the triple epidemic of
153 ZIKV, DENV and CHIKV between 2016 and 2018. Briefly, venous whole blood
154 samples were collected in EDTA tubes and separated plasma/sera samples
155 were kept at -80°C until use. Viral RNA was extracted as described above.

156 Sequencing of the CHIKV RT-LAMP amplicons

157 Genetic characterization of the RT-LAMP amplicons and DNA analysis from
158 one patient sample was performed by the Sanger method as described
159 previously⁹.

160 Statistics

161 Graphs and analysis were done using GraphPad Prism (version 10, GraphPad
162 Software) and MedCalc software (version 19.2.0, MedCalc Software, Ostend,
163 Belgium). Diagnostic parameters were calculated using an online mathematical
164 tool provided by MedCalc (https://www.medcalc.org/calc/diagnostic_test.php).

165 Ethics

166 This study was approved by the Pernambuco State Hematology and
167 Hemotherapy Foundation (HEMOPE-PE) Institutional Review Board (IRB)
168 under protocol CAAE: 43877521.4.00000.5195. Informed consent of all patients
169 included in the present study was waived by the IRB for diagnostic samples.

170

171

172

173

174

175

176

177 RESULTS

178 Establishing an RT-LAMP assay for CHIKV detection

179 To develop an affordable RT-LAMP assay for use in limited-resource settings,
180 we first explored different RT-LAMP mix formulations: the WarmStart LAMP
181 Master Mix and an RT-LAMP formulation containing Bst DNA polymerase 3.0.
182 Side-by-side testing of these mixes demonstrated similar performance in terms
183 of colorimetric readout and real-time detection (Fig. S2 A,B). Despite its
184 efficiency, the high cost of WarmStart LAMP Master Mix could limit its use in
185 low-resource settings. Comparatively, we previously developed an RT-LAMP
186 assay containing Bst DNA polymerase 3.0 at a cost per reaction of < USD \$1⁹,
187 a stark contrast to the USD ~ \$4 per reaction for WarmStart LAMP Mix. Given
188 the versatility and low-cost, we opted to use an RT-LAMP formulation
189 containing Bst DNA polymerase 3.0 and the colorimetric readout for the next
190 phase of the project.

191 Establishing the optimal protocol for visual detection

192 Optimization is a critical step in the development of an RT-LAMP assay. We
193 began by screening incubation time, temperature, concentrations of
194 magnesium, dNTPs, dye (SYBR Green I), and primer combinations. We found
195 that CHIKV genome amplification (10⁵ PFU, cultured virus) occurred at 30
196 minutes after incubation (Fig. S3 A). Positive amplification was detected at
197 incubation temperatures ranging from 59 to 68°C (Fig. S3 B). Optimal reagents
198 concentrations were identified as 8 mM Mg²⁺ and 1.4 mM dNTPs, and SYBR
199 Green I was found to perform optimally at a 1:10 dilution (Fig. S3 C–D, F). All
200 three sets of LAMP primers were required for amplification of the CHIKV
201 genome (Fig. S3 E). These optimal parameters were selected and used for
202 further experiments, as described below.

203 Analytical specificity of CHIKV RT-LAMP assay

204 We next determined the analytical specificity of the assay using a panel of
205 several endemic arboviruses in Latin America that could, in practice, be found in
206 individuals presenting clinical symptoms typically attributed to CHIKV infection
207 under real-life settings. Positive results were obtained only in samples

208 containing CHIKV (Fig. S4). Parallel testing using RT-qPCR agreed with these
209 findings, in which the Cq value for the CHIKV sample was 12.7.

210 **Analytical sensitivity of CHIKV RT-LAMP assay**

211 Our RT-LAMP assay could detect a broad range of CHIKV concentration (from
212 10^5 to 10^{-5} PFU) (Fig. S5). In parallel, these CHIKV serum dilutions were
213 extracted and tested by RT-qPCR. The analytical sensitivity of RT-qPCR was
214 only observed down to 10^{-1} PFU with a Cq value of 33.3 (Fig. S5 and Fig. S6).
215 Probit regression analysis was used to accurately determine the limit of
216 detection (LoD) of our RT-LAMP assay using 10 replicates of each dilution. The
217 LoD of RT-LAMP at 95% probability was estimated in -1.18 PFU (confidence
218 interval [CI] ranging from -2.08 to 0.45), indicating that our RT-LAMP assay
219 exhibits an equivalent analytical sensitivity to the gold standard RT-qPCR assay
220 (Fig. S7 and Table S2).

221 **Detection of CHIKV in virus-spiked human and mosquito samples**

222 We next evaluated the ability of our RT-LAMP assay to detect CHIKV in human
223 biofluids and mosquito samples under controlled conditions. Our RT-LAMP
224 assay was able to detect CHIKV in all spiked samples in both clinically viral
225 loads (Fig. 1 A–I). All specimens were assayed in parallel using RT-qPCR,
226 reporting Cq values (12.7; 12.5; 12.6; 12.7) and (23.1; 22.6; 22.7; 22.7), for both
227 viral loads in serum, saliva, urine and crude lysate of *Ae. aegypti*, respectively
228 (Fig. S8).

229 **Clinical validation in a reference laboratory for arbovirus diagnostics in** 230 **Brazil**

231 We began field validation using patient samples collected from suspected
232 arbovirus infection in Brazil. As the site for the trial, we selected the reference
233 laboratory for arboviruses diagnostics at Fiocruz Pernambuco, Recife,
234 Pernambuco State, which is an area known for simultaneous circulation of
235 arboviruses^{23, 24}. A total of 100 serum specimens double blinded (61 negative
236 and 39 positive samples for CHIKV, as determined by RT-qPCR) were used
237 with Cq values ranging from 12.9 to >40.0 . Our RT-LAMP assay detected
238 CHIKV in 41 specimens, including two specimens that had been deemed

239 negative by RT-qPCR. In contrast, 59 were determined as negative by RT-
240 LAMP (Fig. 2 A). Integrity of RNA in the samples was confirmed using RT-
241 qPCR for RNase (Fig. 2 B). Furthermore, specimens at the detection threshold
242 by RT-qPCR (with Cq values; 35.4, 36.3, 36.9, 37.0 and 37.7) were assayed by
243 RT-LAMP and all reactions showed a positive result, including one sample that
244 had been deemed negative by RT-qPCR with Cq value 37.7 (Fig. S9). Using
245 the Sanger method, we sequenced the second RT-LAMP positive sample that
246 had been deemed indeterminate by RT-qPCR, confirming the accuracy of our
247 test to detect the virus (Fig. S10).

248 In comparison with the RT-qPCR technique, the CHIKV RT-LAMP assay had a
249 clinical sensitivity of 100% (95% confidence interval [CI], 90.97% to 100.00%)
250 and clinical specificity of 96.72% (95% CI, 88.65% to 99.60%). The overall
251 accuracy of the CHIKV RT-LAMP assay was 98.00% (95% CI, 92.96% to
252 99.76%) (Table 1). Taken together, these findings indicate that our RT-LAMP
253 assay exhibits diagnostic performance equivalent to RT-qPCR, highlighting the
254 potential for our assay to be used in clinical settings.

255 **Establishing a lyophilized RT-LAMP assay for CHIKV detection**

256 Field-deployable diagnostics are urgently needed to combat infectious
257 diseases. With this perspective in mind, we have established a lyophilized RT-
258 LAMP for CHIKV diagnostics (Fig. S11 A, B). This started with evaluation of
259 lyophilized and fresh reactions using in vitro-transcribed RNA inputs (300 nM),
260 indicating that our RT-LAMP could be lyophilized and reactivated by adding
261 water (Fig. S11 C). Lastly, we demonstrate that our RT-LAMP platform could be
262 lyophilized and stored at room temperature for at least two weeks (Fig. S11 D,
263 E), suggesting potential for room-temperature storage and distribution without
264 cold chain logistics.

265

266

267

268

269 DISCUSSION

270 Given the lack of readily available vaccines against CHIKV infection, timely and
271 reliable CHIKV diagnosis remains the primary defense against disease spread.
272 In remote and low-resource areas, field-deployable PoC diagnostics are needed
273 to fill this role, ensuring that patients receive timely treatment. Building upon our
274 previous development of PoC diagnostics for Ebola virus²⁵, Zika virus^{8, 9, 26-28}
275 and SARS-CoV-2²⁹, here we present a collaborative effort to develop an RT-
276 LAMP assay for detection of CHIKV.

277 To facilitate the use of our RT-LAMP assay in real-life settings and further
278 prevent false-positives, we identified minimum sample/reaction
279 handling/processing as a critical requirement. Typically, RT-LAMP is performed
280 using a two-step protocol in which two enzymes – a reverse transcriptase and a
281 DNA polymerase – are required, as well as a preceding RNA isolation step. To
282 simplify this, we opted to use Bst DNA polymerase 3.0 (NEB), a single enzyme
283 that exhibits both reverse-transcriptase and polymerase activity⁷, resulting in a
284 one-step protocol. While several two-step RT-LAMP protocols have been
285 described for CHIKV detection^{21, 30}, the one-step protocol described here
286 overcomes the need for multiple enzymes and sample processing steps.

287 A key consideration when evaluating PoC diagnostics is the ability to detect
288 viral RNA in patients with low viral load. Serum samples collected from patients
289 1-8 days after illness onset typically have a high viral load (1×10^5 copies/mL)³¹.
290 In contrast, a significant reduction in CHIKV viral load (1×10^2 - 1×10^1 copies/mL)
291 is usually observed in samples collected 8 days after illness onset³¹. Here, we
292 showed that our RT-LAMP assay was able to provide detection well within
293 clinically relevant concentrations (from 10^5 to 10^{-5} PFU) - a similar analytical
294 sensitivity to RT-qPCR. In agreement with our findings, some reports have
295 documented that the analytical sensitivity of RT-LAMP is similar or even
296 superior to RT-qPCR for CHIKV detection^{21, 30, 32}.

297 Several other platforms have been developed for CHIKV diagnostics. However,
298 PoC deployment of many of these technologies is dependent on multiple liquid-
299 handling steps, reliable access to electricity, technically skilled operators, and
300 sophisticated and proprietary hardware^{21, 32-35}. Moreover, many of these

301 technologies have only been evaluated using spiked-virus samples or with a
302 limited number of patient samples.

303 Our RT-LAMP assay comes at a significantly reduced cost when compared to
304 RT-qPCR and RT-LAMP commercial kits. The cost of each RT-LAMP reaction
305 in this study was < USD \$1, a meaningful contrast to the USD \$11-25 required
306 for each RT-qPCR test^{9, 15} and USD \$ 4 required for RT-LAMP reactions using
307 commercial kits. However, we believe that this cost can be reduced even further
308 by the potential replacement of commercial research-grade enzymes with
309 locally manufactured reagents^{36 37}.

310 In summary, we have developed a rapid, low-cost, lyophilized RT-LAMP assay
311 for the detection of CHIKV in patient and mosquito samples. Overall, our RT-
312 LAMP assay displayed high accuracy and is an inexpensive molecular platform
313 for the diagnosis of CHIKV, and may serve as a basis for the development of
314 alternative diagnostic methods.

315

316

317

318

319

320

321

322

323

324

325

326

327 Funding statement

328 This work was supported by funds to L.P. and K.P. from the International
329 Development Research Centre (IDRC, grant 109434). L.P. is funded by the
330 Fiocruz Inova Program, Canadian International Development Research Centre
331 (108410-001) and the Foundation for Science and Technology of Pernambuco -
332 FACEPE, Brazil (Grant No. APQ-0154-2.12/16). S.S. was supported by a Ph.D.
333 fellowship sponsored by the Foundation for Science and Technology of
334 Pernambuco (FACEPE), reference number IBPG-1321-2.12/18, and currently is
335 supported by a Postdoctoral Fellowship sponsored by the University of Toronto,
336 Canada. J.J.F.M. is funded by the Foundation for Science and Technology of
337 Pernambuco - FACEPE, Brazil (Grant No. APQ-0741-4.01/22). A.K. is funded
338 by the UK Medical Research Council (MC_UU_12014/8, MC_UU_00034/4).
339 The funders had no role in study design, data collection and analysis, decision
340 to publish, or preparation of the manuscript.

341 Acknowledgments

342 We express our sincere gratitude to the Pernambuco State Central Laboratory
343 (LACEN/PE) for providing the patient samples used in this study. We thank Dr.
344 Roberta Bronzoni from the Federal University of Mato Grosso (UFMT), Brazil,
345 and Dr. Laura Gil from Fiocruz Pernambuco for providing the Mayaro virus and
346 Zika virus MR766 strain. Moreover, we thank Dr. Constância Ayres, Dr. Marcelo
347 Paiva, Dr. Duschinka Guedes and Dr. Larissa Krovovsky from the Department
348 of Entomology, Fiocruz Pernambuco, for providing the mosquitoes used in this
349 study.

350 Author contributions

351 S.S. and L.P. conceived the work. S.S., J.J.F.M., A.L.L.D., D.G.A.C., and J.B.S.
352 conducted the experiments. S.S. and L.P. performed data analysis and
353 interpretation. S.S. wrote the original draft. S.S., Q. M., R. P. G. M., B. N. R. S.,
354 A.K., K.P. and L.P. wrote the final draft. S.S. and L.P. supervised the work. All
355 authors critically revised and approved the final version of the manuscript.

356 Competing interests

357 S.S. and L.P. are the inventors of the RT-LAMP protocol described throughout
358 this study and both authors have other patents related to this technology (BR 10
359 2019 027711 4, filed 23 Dec 2019). The other authors declare no competing
360 interests.

361

362

363

364

365

366

367

368

369

370

371


372

373

374

375

376




377

378 **Figure 1. CHIKV detection in virus-spiked specimens.** Specimens including
 379 serum, saliva, urine and crude lysate of *Ae. aegypti* mosquitoes were spiked
 380 with two viral loads: 10^6 or 10^3 PFU/mL. Then, these samples were directly
 381 assayed (A–I). To compare the results of RT-LAMP with RT-qPCR, viral RNA
 382 was extracted from the same specimens and then tested. The Cq values are
 383 described at the bottom of the figure. RT-LAMP products were visualized by
 384 three different methods: naked eye as visualized by addition of SYBR Green I
 385 (A, C, E and G), fluorescence under UV light (B, D, F and H), or looking for a
 386 typical band pattern of a successful RT-LAMP reaction using gel
 387 electrophoresis (2 %) (I). Legends in (A–I) are: (1): uninfected biological
 388 specimen (serum, saliva, urine and crude lysate of *Ae. aegypti* mosquitos); (2):
 389 specimen spiked with 10^6 PFU/mL; (3): specimen spiked with 10^3 PFU/mL. M:
 390 molecular weight marker. ND: not detected.

391

392



393

394 **Figure 2. Performance of the diagnostic system in a reference laboratory.**

395 A total of 100 serum samples were tested for CHIKV by RT-LAMP and RT-
 396 qPCR. Of these, 39 were positive and 61 were negative for CHIKV as
 397 determined by RT-qPCR and 41 were positive and 59 were negative for CHIKV
 398 as determined by RT-LAMP (A). The same samples were tested using the RT-
 399 qPCR protocol for detection of the endogenous Ribonuclease P (RNase P)
 400 gene, where the Cq value in these specimens ranged from 19.2 to 37.4 (B).
 401 According to the RT-qPCR protocol used, the Cq threshold for CHIKV positivity
 402 was ≤ 37 (represented by the dashed line in panel A) and the Cq threshold for
 403 RNase P endogenous control was ≤ 40 . Red triangles represent specimens
 404 identified as positive and blue circles represent specimens identified as
 405 negative by our RT-LAMP assay.

406

407

408

409

410

411 **Table 1.** Diagnostic performance of RT-LAMP assay for CHIKV diagnostics
 412 using patient samples.

	RT-qPCR +	RT-qPCR -	Total
RT-LAMP +	39	2	41
RT-LAMP -	0	59	59
Total	39	61	
Sensitivity	100 % (95% CI 90.97% to 100.00%)		
Specificity	96.72 % (95% CI 88.65% to 99.60%)		
CHIKV prevalence	39.00% (95% CI 29.40% to 49.27%)		
Positive Predictive Value (PPV)	95.12% (95% CI 83.30% to 98.70%)		
Negative Predictive Value (NPV)	100 % (95% CI 93.94% to 100.00%)		
Accuracy	98.00% (95% CI 92.96% to 99.76%)		

413

414

415

416

417

418

419

420

421

422

423

424

425

426 **References**


- 427 (1) Kuhn, R. J. *Togaviridae*. In *Fields Virology*, 2013.
- 428 (2) Weaver, S. C.; Lecuit, M. Chikungunya virus and the global spread of a mosquito-borne
429 disease. *N Engl J Med* **2015**, *372* (13), 1231-1239. DOI: 10.1056/NEJMra1406035.
- 430 (3) Brito Ferreira, M. L.; Militão de Albuquerque, M. F. P.; de Brito, C. A. A.; de Oliveira França,
431 R. F.; Porto Moreira, Á.; de Moraes Machado, M.; da Paz Melo, R.; Medialdea-Carrera, R.;
432 Dornelas Mesquita, S.; Lopes Santos, M.; et al. Neurological disease in adults with Zika and
433 chikungunya virus infection in Northeast Brazil: a prospective observational study. *Lancet*
434 *Neurol* **2020**, *19* (10), 826-839. DOI: 10.1016/S1474-4422(20)30232-5.
- 435 (4) Schilte, C.; Staikowsky, F.; Staikovsky, F.; Couderc, T.; Madec, Y.; Carpentier, F.; Kassab, S.;
436 Albert, M. L.; Lecuit, M.; Michault, A. Chikungunya virus-associated long-term arthralgia: a 36-
437 month prospective longitudinal study. *PLoS Negl Trop Dis* **2013**, *7* (3), e2137. DOI:
438 10.1371/journal.pntd.0002137.
- 439 (5) Queyriaux, B.; Simon, F.; Grandadam, M.; Michel, R.; Tolou, H.; Boutin, J. P. Clinical burden
440 of chikungunya virus infection. *Lancet Infect Dis* **2008**, *8* (1), 2-3. DOI: 10.1016/S1473-
441 3099(07)70294-3.
- 442 (6) Lanciotti, R. S.; Kosoy, O. L.; Laven, J. J.; Panella, A. J.; Velez, J. O.; Lambert, A. J.; Campbell,
443 G. L. Chikungunya virus in US travelers returning from India, 2006. *Emerg Infect Dis* **2007**, *13*
444 (5), 764-767. DOI: 10.3201/eid1305.070015.
- 445 (7) Silva, S. J. R. D.; Pardee, K.; Pena, L. Loop-Mediated Isothermal Amplification (LAMP) for the
446 Diagnosis of Zika Virus: A Review. *Viruses* **2019**, *12* (1). DOI: 10.3390/v12010019.
- 447 (8) Silva, S. J. R. D.; Paiva, M. H. S.; Guedes, D. R. D.; Krovovsky, L.; Melo, F. L.; Silva, M. A. L. D.;
448 Silva, A. D.; Ayres, C. F. J.; Pena, L. J. Development and Validation of Reverse Transcription
449 Loop-Mediated Isothermal Amplification (RT-LAMP) for Rapid Detection of ZIKV in Mosquito
450 Samples from Brazil. *Sci Rep* **2019**, *9* (1), 4494. DOI: 10.1038/s41598-019-40960-5.
- 451 (9) da Silva, S. J. R.; Pardee, K.; Balasuriya, U. B. R.; Pena, L. Development and validation of a
452 one-step reverse transcription loop-mediated isothermal amplification (RT-LAMP) for rapid
453 detection of ZIKV in patient samples from Brazil. *Sci Rep* **2021**, *11* (1), 4111. DOI:
454 10.1038/s41598-021-83371-1.
- 455 (10) Notomi, T.; Okayama, H.; Masubuchi, H.; Yonekawa, T.; Watanabe, K.; Amino, N.; Hase, T.
456 Loop-mediated isothermal amplification of DNA. *Nucleic Acids Res* **2000**, *28* (12), E63.
- 457 (11) Mori, Y.; Notomi, T. Loop-mediated isothermal amplification (LAMP): a rapid, accurate,
458 and cost-effective diagnostic method for infectious diseases. *J Infect Chemother* **2009**, *15* (2),
459 62-69. DOI: 10.1007/s10156-009-0669-9.
- 460 (12) Lopez-Jimena, B.; Bekaert, M.; Bakheit, M.; Frischmann, S.; Patel, P.; Simon-Loriere, E.;
461 Lambrechts, L.; Duong, V.; Dussart, P.; Harold, G.; et al. Development and validation of four
462 one-step real-time RT-LAMP assays for specific detection of each dengue virus serotype. *PLoS*
463 *Negl Trop Dis* **2018**, *12* (5), e0006381. DOI: 10.1371/journal.pntd.0006381.
- 464 (13) Bonney, L. C.; Watson, R. J.; Slack, G. S.; Bosworth, A.; Wand, N. I. V.; Hewson, R. A flexible
465 format LAMP assay for rapid detection of Ebola virus. *PLoS Negl Trop Dis* **2020**, *14* (7),
466 e0008496. DOI: 10.1371/journal.pntd.0008496.
- 467 (14) Huang, W. E.; Lim, B.; Hsu, C. C.; Xiong, D.; Wu, W.; Yu, Y.; Jia, H.; Wang, Y.; Zeng, Y.; Ji, M.;
468 et al. RT-LAMP for rapid diagnosis of coronavirus SARS-CoV-2. *Microb Biotechnol* **2020**. DOI:
469 10.1111/1751-7915.13586.
- 470 (15) Lu, S.; Duplat, D.; Benitez-Bolivar, P.; León, C.; Villota, S. D.; Veloz-Villavicencio, E.; Arévalo,
471 V.; Jaenes, K.; Guo, Y.; Cicek, S.; et al. Multicenter international assessment of a SARS-CoV-2
472 RT-LAMP test for point of care clinical application. *PLoS One* **2022**, *17* (5), e0268340. DOI:
473 10.1371/journal.pone.0268340.
- 474 (16) Lamb, L. E.; Bartolone, S. N.; Ward, E.; Chancellor, M. B. Rapid detection of novel
475 coronavirus/Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by reverse


- 476 transcription-loop-mediated isothermal amplification. *PLoS One* **2020**, *15* (6), e0234682. DOI:
 477 10.1371/journal.pone.0234682.
- 478 (17) Dao Thi, V. L.; Herbst, K.; Boerner, K.; Meurer, M.; Kremer, L. P.; Kirrmaier, D.;
 479 Freistaedter, A.; Papagiannidis, D.; Galmozzi, C.; Stanifer, M. L.; et al. A colorimetric RT-LAMP
 480 assay and LAMP-sequencing for detecting SARS-CoV-2 RNA in clinical samples. *Sci Transl Med*
 481 **2020**, *12* (556). DOI: 10.1126/scitranslmed.abc7075.
- 482 (18) Huang, X.; Tang, G.; Ismail, N.; Wang, X. Developing RT-LAMP assays for rapid diagnosis of
 483 SARS-CoV-2 in saliva. *EBioMedicine* **2022**, *75*, 103736. DOI: 10.1016/j.ebiom.2021.103736.
- 484 (19) Silva, S. J. R. D.; Silva, C.; Guarines, K.; Mendes, R.; Pardee, K. M.; Kohl, A.; Pena, L. Clinical
 485 and Laboratory Diagnosis of SARS-CoV-2, the Virus Causing COVID-19. *ACS Infect Dis* **2020**. DOI:
 486 10.1021/acscinfecdis.0c00274.
- 487 (20) da Silva, S. J. R.; do Nascimento, J. C. F.; Germano Mendes, R. P.; Guarines, K. M.; Targino
 488 Alves da Silva, C.; da Silva, P. G.; de Magalhães, J. J. F.; Vigar, J. R. J.; Silva-Júnior, A.; Kohl, A.; et
 489 al. Two Years into the COVID-19 Pandemic: Lessons Learned. *ACS Infect Dis* **2022**. DOI:
 490 10.1021/acscinfecdis.2c00204.
- 491 (21) Lopez-Jimena, B.; Wehner, S.; Harold, G.; Bakheit, M.; Frischmann, S.; Bekaert, M.; Faye,
 492 O.; Sall, A. A.; Weidmann, M. Development of a single-tube one-step RT-LAMP assay to detect
 493 the Chikungunya virus genome. *PLoS Negl Trop Dis* **2018**, *12* (5), e0006448. DOI:
 494 10.1371/journal.pntd.0006448.
- 495 (22) Warfel, K. F.; Williams, A.; Wong, D. A.; Sobol, S. E.; Desai, P.; Li, J.; Chang, Y. F.; DeLisa, M.
 496 P.; Karim, A. S.; Jewett, M. C. A Low-Cost, Thermostable, Cell-Free Protein Synthesis Platform
 497 for On-Demand Production of Conjugate Vaccines. *ACS Synth Biol* **2023**, *12* (1), 95-107. DOI:
 498 10.1021/acssynbio.2c00392.
- 499 (23) Silva, S. J. R. D.; Magalhães, J. J. F.; Pena, L. Simultaneous Circulation of DENV, CHIKV, ZIKV
 500 and SARS-CoV-2 in Brazil: an Inconvenient Truth. *One Health* **2021**, *12*, 100205. DOI:
 501 10.1016/j.onehlt.2020.100205.
- 502 (24) Magalhaes, T.; Braga, C.; Cordeiro, M. T.; Oliveira, A. L. S.; Castanha, P. M. S.; Maciel, A. P.
 503 R.; Amancio, N. M. L.; Gouveia, P. N.; Peixoto-da-Silva, V. J.; Peixoto, T. F. L.; et al. Zika virus
 504 displacement by a chikungunya outbreak in Recife, Brazil. *PLoS Negl Trop Dis* **2017**, *11* (11),
 505 e0006055. DOI: 10.1371/journal.pntd.0006055.
- 506 (25) Pardee, K.; Green, A. A.; Ferrante, T.; Cameron, D. E.; DaleyKeyser, A.; Yin, P.; Collins, J. J.
 507 Paper-based synthetic gene networks. *Cell* **2014**, *159* (4), 940-954. DOI:
 508 10.1016/j.cell.2014.10.004.
- 509 (26) Pardee, K.; Green, A. A.; Takahashi, M. K.; Braff, D.; Lambert, G.; Lee, J. W.; Ferrante, T.;
 510 Ma, D.; Donghia, N.; Fan, M.; et al. Rapid, Low-Cost Detection of Zika Virus Using
 511 Programmable Biomolecular Components. *Cell* **2016**, *165* (5), 1255-1266. DOI:
 512 10.1016/j.cell.2016.04.059.
- 513 (27) Karlikow, M.; da Silva, S. J. R.; Guo, Y.; Cicek, S.; Krokovsky, L.; Homme, P.; Xiong, Y.; Xu, T.;
 514 Calderón-Peláez, M. A.; Camacho-Ortega, S.; et al. Field validation of the performance of
 515 paper-based tests for the detection of the Zika and chikungunya viruses in serum samples. *Nat*
 516 *Biomed Eng* **2022**, *6* (3), 246-256. DOI: 10.1038/s41551-022-00850-0.
- 517 (28) Jaenes, K.; Ribeiro da Silva, S. J.; Vigar, J. R. J.; Wu, K.; Norouzi, M.; Bayat, P.; Karlikow, M.;
 518 Cicek, S.; Guo, Y.; Green, A. A.; et al. Design to Implementation Study for Development and
 519 Patient Validation of Paper-Based Toehold Switch Diagnostics. *J Vis Exp* **2022**, (184). DOI:
 520 10.3791/63223.
- 521 (29) Amalfitano, E.; Karlikow, M.; Norouzi, M.; Jaenes, K.; Cicek, S.; Masum, F.; Sadat Mousavi,
 522 P.; Guo, Y.; Tang, L.; Sydor, A.; et al. A glucose meter interface for point-of-care gene circuit-
 523 based diagnostics. *Nat Commun* **2021**, *12* (1), 724. DOI: 10.1038/s41467-020-20639-6.
- 524 (30) Parida, M. M.; Santhosh, S. R.; Dash, P. K.; Tripathi, N. K.; Lakshmi, V.; Mamidi, N.;
 525 Shrivastva, A.; Gupta, N.; Saxena, P.; Babu, J. P.; et al. Rapid and real-time detection of
 526 Chikungunya virus by reverse transcription loop-mediated isothermal amplification assay. *J Clin*
 527 *Microbiol* **2007**, *45* (2), 351-357. DOI: 10.1128/JCM.01734-06.

- 528 (31) Tun, Y. M.; Charunwatthana, P.; Duangdee, C.; Satayarak, J.; Suthisawat, S.; Likhit, O.;
529 Lakhotia, D.; Kosoltanapiwat, N.; Sukphopetch, P.; Boonnak, K. Virological, Serological and
530 Clinical Analysis of Chikungunya Virus Infection in Thai Patients. *Viruses* **2022**, *14* (8). DOI:
531 10.3390/v14081805.
- 532 (32) Saechue, B.; Kamiyama, N.; Wang, Y.; Fukuda, C.; Watanabe, K.; Soga, Y.; Goto, M.;
533 Dewayani, A.; Ariki, S.; Hirose, H.; et al. Development of a portable reverse transcription loop-
534 mediated isothermal amplification system to detect the E1 region of Chikungunya virus in a
535 cost-effective manner. *Genes Cells* **2020**, *25* (9), 615-625. DOI: 10.1111/gtc.12797.
- 536 (33) Hayashida, K.; Orba, Y.; Sequeira, P. C.; Sugimoto, C.; Hall, W. W.; Eshita, Y.; Suzuki, Y.;
537 Runtuwene, L.; Brasil, P.; Calvet, G.; et al. Field diagnosis and genotyping of chikungunya virus
538 using a dried reverse transcription loop-mediated isothermal amplification (LAMP) assay and
539 MinION sequencing. *PLoS Negl Trop Dis* **2019**, *13* (6), e0007480. DOI:
540 10.1371/journal.pntd.0007480.
- 541 (34) Nasrin, F.; Tsuruga, K.; Utomo, D. I. S.; Chowdhury, A. D.; Park, E. Y. Design and Analysis of
542 a Single System of Impedimetric Biosensors for the Detection of Mosquito-Borne Viruses.
543 *Biosensors (Basel)* **2021**, *11* (10). DOI: 10.3390/bios11100376.
- 544 (35) Sood, S. K.; Mahajan, I. Wearable IoT sensor based healthcare system for identifying and
545 controlling chikungunya virus. *Comput Ind* **2017**, *91*, 33-44. DOI:
546 10.1016/j.compind.2017.05.006.
- 547 (36) Matute, T.; Nuñez, I.; Rivera, M.; Reyes, J.; Blázquez-Sánchez, P.; Arce, A.; Brown, A. J.;
548 Gandini, C.; Molloy, J.; Ramírez-Sarmiento, C. A.; et al. Homebrew reagents for low-cost RT-
549 LAMP. *J Biomol Tech* **2021**, *32* (3), 114-120. DOI: 10.7171/jbt.21-3203-006.
- 550 (37) Guzman-Chavez, F.; Arce, A.; Adhikari, A.; Vadhin, S.; Pedroza-Garcia, J. A.; Gandini, C.;
551 Ajioka, J. W.; Molloy, J.; Sanchez-Nieto, S.; Varner, J. D.; et al. Constructing Cell-Free Expression
552 Systems for Low-Cost Access. *ACS Synth Biol* **2022**, *11* (3), 1114-1128. DOI:
553 10.1021/acssynbio.1c00342.

554

555



A**B**